Atypical Teratoid/Rhabdoid Tumor with Retained SMARCB1 (INI1) Expression and Rare SMARCA4 Gene Mutation: A Case Report of a Pediatric Patient

被引:0
作者
Maliskina, Anna Marija [1 ]
Franckevica, Ivanda [2 ,3 ]
Visnevska-Preciniece, Zelma [4 ]
Grutupa, Marika [4 ]
Kovalova, Zanna [4 ,5 ]
机构
[1] Riga Stradins Univ, Fac Med, Dzirciema St 16, LV-1007 Riga, Latvia
[2] Riga Stradins Univ, Dept Pathol, 9c Kuldigas St, LV-1007 Riga, Latvia
[3] Childrens Clin Univ Hosp, Dept Pathol, LV-1004 Riga, Latvia
[4] Childrens Clin Univ Hosp, Dept Hematol & Oncol, LV-1004 Riga, Latvia
[5] Childrens Clin Univ Hosp, Dept Pediat, LV-1004 Riga, Latvia
关键词
atypical teratoid/rhabdoid tumor; retained INI1; SMARCA4; CENTRAL-NERVOUS-SYSTEM; TERATOID RHABDOID TUMOR; SURVIVAL; CHILDREN; THERAPY; AT/RT;
D O I
10.3390/reports7020028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atypical teratoid/rhabdoid tumors (AT/RT) are highly aggressive tumors of the central nervous system (CNS), accounting for 1-3% of all pediatric CNS tumors. In general, AT/RTs are associated with biallelic inactivation of SMARCB1, resulting in the loss of expression of the integrase interactor 1 (INI1) protein. In this report, we describe the clinical course of an infant patient who presented with fatigue, postprandial vomiting, and disability of left side movement. Histological examination revealed classical features indicative of rhabdoid tumors, yet an atypical immunohistochemical profile with preserved INI1 expression was observed. Molecular diagnostics further elucidated the presence of a heterozygous frameshift variant, SMARCA4 c.2693del, p.(Asn898Thrfs*12), underscoring the distinctive genetic foundations of the case. Surgical resection of the tumor was administered with subsequent chemotherapy to the patient, but the condition worsened dynamically, and a decision was made to give the patient palliative therapy. We report on a patient with AT/RT caused by a rare mutation of the SMARCA4 gene and an aggressive course of disease to provide more information and characteristics of these tumors.
引用
收藏
页数:9
相关论文
共 29 条
  • [1] Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor
    Alva, Elizabeth
    Rubens, Jeffrey
    Chi, Susan
    Rosenberg, Tom
    Reddy, Alyssa
    Raabe, Eric H.
    Margol, Ashley
    [J]. NEOPLASIA, 2023, 37
  • [2] Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007
    Bartelheim, Kerstin
    Nemes, Karolina
    Seeringer, Angela
    Kerl, Kornelius
    Buechner, Jochen
    Boos, Joachim
    Graf, Norbert
    Duerken, Matthias
    Gerss, Joachim
    Hasselblatt, Martin
    Kortmann, Rolf-Dieter
    Teichert von Luettichau, Irene
    Nagel, Inga
    Nygaard, Randi
    Oyen, Florian
    Quiroga, Eduardo
    Schlegel, Paul-Gerhardt
    Schmid, Irene
    Schneppenheim, Reinhard
    Siebert, Reiner
    Solano-Paez, Palma
    Timmermann, Beate
    Warmuth-Metz, Monika
    Fruehwald, Michael Christoph
    [J]. CANCER MEDICINE, 2016, 5 (08): : 1765 - 1775
  • [3] Atypical teratoid/rhabdoid tumors: challenges and search for solutions
    Biswas, Ahitagni
    Kashyap, Lakhan
    Kakkar, Aanchal
    Sarkar, Chitra
    Julka, Pramod Kumar
    [J]. CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 115 - 125
  • [4] Atypical teratoid rhabdoid tumor of the brain: case series and review of literature
    Biswas, Ahitagni
    Goyal, Shikha
    Puri, Tarun
    Das, Prasenjit
    Sarkar, Chitra
    Julka, Pramod Kumar
    Bakhshi, Sameer
    Rath, Goura Kishor
    [J]. CHILDS NERVOUS SYSTEM, 2009, 25 (11) : 1495 - 1500
  • [5] Atypical teratoid/rhabdoid tumor with retained INI1 (SMARCB1) expression and loss of BRG1 (SMARCA4)
    Bookhout, Christine
    Bouldin, Thomas W.
    Ellison, David W.
    [J]. NEUROPATHOLOGY, 2018, 38 (03) : 305 - 308
  • [6] Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis
    Buscariollo, Daniela L.
    Park, Henry S.
    Roberts, Kenneth B.
    Yu, James B.
    [J]. CANCER, 2012, 118 (17) : 4212 - 4219
  • [7] Atypical Teratoid Rhabdoid Tumor: Proposal of a Diagnostic Pathway Based on Clinical Features and Neuroimaging Findings
    Calandrelli, Rosalinda
    Massimi, Luca
    Pilato, Fabio
    Verdolotti, Tommaso
    Ruggiero, Antonio
    Attina, Giorgio
    Gessi, Marco
    Colosimo, Cesare
    [J]. DIAGNOSTICS, 2023, 13 (03)
  • [8] Rhabdoid Tumor Predisposition Syndrome: From Clinical Suspicion to General Management
    Del Baldo, Giada
    Carta, Roberto
    Alessi, Iside
    Merli, Pietro
    Agolini, Emanuele
    Rinelli, Martina
    Boccuto, Luigi
    Milano, Giuseppe Maria
    Serra, Annalisa
    Carai, Andrea
    Locatelli, Franco
    Mastronuzzi, Angela
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system
    Dufour, Christelle
    Beaugrand, Annick
    Le Deley, Marie Cecile
    Bourdeaut, Franck
    Andre, Nicolas
    Leblond, Pierre
    Bertozzi, Anne-Isabelle
    Frappaz, Didier
    Rialland, Xavier
    Fouyssac, Fanny
    Edan, Christine
    Grill, Jacques
    Quidot, Marion
    Varlet, Pascale
    [J]. CANCER, 2012, 118 (15) : 3812 - 3821
  • [10] ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance
    Federico, Aniello
    Thomas, Christian
    Miskiewicz, Katarzyna
    Woltering, Niklas
    Zin, Francesca
    Nemes, Karolina
    Bison, Brigitte
    Johann, Pascal D.
    Hawes, Debra
    Bens, Susanne
    Kordes, Uwe
    Albrecht, Steffen
    Dohmen, Hildegard
    Hauser, Peter
    Keyvani, Kathy
    van Landeghem, Frank K. H.
    Lund, Eva Lobner
    Scheie, David
    Mawrin, Christian
    Monoranu, Camelia-Maria
    Ulhoi, Benedicte Parm
    Pietsch, Torsten
    Reinhard, Harald
    Riemenschneider, Markus J.
    Sehested, Astrid
    Sumerauer, David
    Siebert, Reiner
    Paulus, Werner
    Fruehwald, Michael C.
    Kool, Marcel
    Hasselblatt, Martin
    [J]. ACTA NEUROPATHOLOGICA, 2022, 143 (06) : 697 - 711